2025 Targeted Therapies of Lung Cancer (TTLC) - Posters-PP01.28 Multiplex immunofluorescence analysis of tumor microenvironment improves prediction of immunotherapy efficacy in NSCLC.

PP01.28 Multiplex immunofluorescence analysis of tumor microenvironment improves prediction of immunotherapy efficacy in NSCLC.

Back to course

Pdf Summary

The study explores the potential of quantitative multiplex immunofluorescence (mIF) in predicting the efficacy of immunotherapy in patients with non-small cell lung cancer (NSCLC). Immunotherapy has shown variable responses among patients, and identifying biomarkers for predicting its effectiveness remains challenging. The research, conducted at a single center, involves the analysis of mIF samples from NSCLC patients who were treated with PD-(L)1 inhibitors, either alone or combined with CTLA-4 or other immune-modulating agents, excluding chemotherapy.<br /><br />mIF markers such as CD8, PD-1, FOXP3, PD-L1, and cytokeratin were assessed in the study to determine their role in treatment outcomes. The immune cell counts in these samples were categorized as high or low, using cutoff values optimized for progression-free survival (PFS). Statistical models including Cox proportional-hazard models were used to estimate hazard ratios (HRs) for PFS and overall survival (OS), with analysis focusing on both univariate and multivariate approaches.<br /><br />The findings suggest that higher immune cell infiltration, as measured by mIF, correlates with improved clinical outcomes following immunotherapy. Thus, integrating immune profiling with the existing biomarkers could be instrumental in identifying NSCLC patients who would most likely benefit from immunotherapy treatments.<br /><br />Overall, this research underscores the value of mIF in enhancing the prediction of immunotherapy effectiveness and paves the way for better-targeted treatments by improving patient selection for immunotherapy in NSCLC. The study involves contributions from a team led by Edoardo Garbo and was conducted at multiple reputable institutions including the Dana-Farber Cancer Institute and Harvard Medical School.

Asset Subtitle

Edoardo Garbo

Keywords

quantitative multiplex immunofluorescence

immunotherapy

non-small cell lung cancer

NSCLC

biomarkers

PD-(L)1 inhibitors

immune cell infiltration

progression-free survival

Cox proportional-hazard models

Dana-Farber Cancer Institute